0102030405
Sofosbuvir CAS No. 1190307-88-0 Antiviral Pharmaceutical Raw Material
02
introduce
introduce
Sofosbuvir is a potent oral nucleotide analogue and core antiviral API, acting as a selective inhibitor of HCV NS5B RNA-dependent RNA polymerase. It is a prodrug metabolized to the active triphosphate form, blocking hepatitis C virus (HCV) replication. Approved for chronic HCV infection.
Our products comply with strict international standards to ensure high purity, stable efficacy, and reliable supply.
02
Physical and chemical properties
Sofosbuvir exhibits key physical and chemical characteristics supporting its pharmaceutical and research applications, as follows:
- Melting Point: 122-124 °C
- Density: 1.4±0.1 g/cm³
- Solubility: Slightly soluble in DMSO and methanol
- Storage Temperature: Hygroscopic; store at -20 °C in a freezer under inert atmosphere
- Melting Point: 122-124 °C
- Density: 1.4±0.1 g/cm³
- Solubility: Slightly soluble in DMSO and methanol
- Storage Temperature: Hygroscopic; store at -20 °C in a freezer under inert atmosphere
1. More convenient administration
It is the world's first oral drug for hepatitis C, no injection required. It allows some hepatitis C patients to get rid of the dependence on interferon, filling the gap in oral anti-hepatitis C treatment.
It is the world's first oral drug for hepatitis C, no injection required. It allows some hepatitis C patients to get rid of the dependence on interferon, filling the gap in oral anti-hepatitis C treatment.
2. Remarkable inhibitory effect
It can rapidly reduce the hepatitis C virus load in the body and achieve more than 99% viral inhibition in a short time. Compared with some hepatitis C drugs with slow onset, it can control viral replication much faster.
It can rapidly reduce the hepatitis C virus load in the body and achieve more than 99% viral inhibition in a short time. Compared with some hepatitis C drugs with slow onset, it can control viral replication much faster.
3. Low drug resistance risk
It has a high genetic barrier to drug resistance, and basically no drug-resistant variants appear when used in combination with other hepatitis C drugs; a small amount of mild drug resistance is occasionally seen only when used as monotherapy, and these drug-resistant viral strains are still sensitive to other hepatitis C drugs, it is more stable for long-term treatment.
4. Wide application range
It can be used to treat hepatitis C virus genotypes 1 to 6. Compared with hepatitis C drugs that can only treat a few genotypes, it is suitable for more hepatitis C patients with different genotypes.
It can be used to treat hepatitis C virus genotypes 1 to 6. Compared with hepatitis C drugs that can only treat a few genotypes, it is suitable for more hepatitis C patients with different genotypes.
5. Good targeting and combination therapy
As a prodrug, it is metabolized into an active form to exert its effect only in the liver, acting on the lesion site accurately with little impact on normal human cells; it can also be used in combination with a variety of hepatitis C drugs, and different treatment regimens can be matched according to patients' conditions.
As a prodrug, it is metabolized into an active form to exert its effect only in the liver, acting on the lesion site accurately with little impact on normal human cells; it can also be used in combination with a variety of hepatitis C drugs, and different treatment regimens can be matched according to patients' conditions.
It is mainly used for the treatment of chronic hepatitis C virus (HCV) infection and is a first-line drug for hepatitis C treatment. The specific application scenarios include:
1. Combined with other drugs (ribavirin, velpatasvir, NS5A inhibitors, etc.) for the treatment of patients with chronic HCV genotype 1-6 infections, which is the clinical preferred combination therapy regimen.
2. Used in interferon-free hepatitis C treatment regimens, it can replace traditional interferon injection and is suitable for hepatitis C patients who are intolerant or ineligible for interferon.
3. Used for hepatitis C patients with hepatocellular carcinoma (HCC) awaiting liver transplantation, and antiviral treatment for such patients can be carried out for up to 48 weeks to delay disease progression.
1. Combined with other drugs (ribavirin, velpatasvir, NS5A inhibitors, etc.) for the treatment of patients with chronic HCV genotype 1-6 infections, which is the clinical preferred combination therapy regimen.
2. Used in interferon-free hepatitis C treatment regimens, it can replace traditional interferon injection and is suitable for hepatitis C patients who are intolerant or ineligible for interferon.
3. Used for hepatitis C patients with hepatocellular carcinoma (HCC) awaiting liver transplantation, and antiviral treatment for such patients can be carried out for up to 48 weeks to delay disease progression.
We implement strict full-process quality control, with each batch of Sofosbuvir undergoing rigorous testing of key indicators including purity, solubility, stability, chiral purity, and impurity content to meet standards.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and production needs.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and production needs.
As a landmark HCV therapeutic, Sofosbuvir has revolutionized chronic hepatitis C treatment with its pan-genotypic efficacy, high safety profile, and oral convenience. It plays a critical role in achieving high sustained virologic response (SVR) rates, enabling HCV cure in millions of patients. With our exceptional product quality, reliable supply capacity, and professional support, we are committed to providing high-quality Sofosbuvir API for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Sofosbuvir to meet your needs in pharmaceutical formulation, antiviral research, and clinical treatment. Contact us for more product details and cooperation support.
Choose our Sofosbuvir to meet your needs in pharmaceutical formulation, antiviral research, and clinical treatment. Contact us for more product details and cooperation support.